Navigation Links
Nanotherapeutics Awarded Defense Department Contract for Advanced Development and Manufacturing of Medical Countermeasures
Date:4/10/2013

Alachua, FL (PRWEB) April 10, 2013

Nanotherapeutics, Inc., announced it has been awarded a Department of Defense’s (DOD) contract to establish Medical Countermeasures Advanced Development and Manufacturing (MCM ADM) capability dedicated to meet the needs of the DOD. The MCM ADM capabilities established by Nanotherapeutics will allow the DOD to more efficiently and expeditiously develop Medical Countermeasures (MCM) to protect and treat military populations against chemical, biological, radiological, and nuclear (CBRN) attacks and outbreaks of naturally occurring emerging and genetically engineered infectious diseases.

The contract was granted to Nanotherapeutics, as the prime contractor, and its industry partners after a highly competitive bid process. The ultimate goal for the award is to reduce the overall time and cost associated with the development and manufacturing of Food and Drug Administration approved MCMs.

Headquartered in Alachua, FL, Nanotherapeutics will integrate into a new state-of-the-art facility flexible, single use, disposable equipment that can provide our military’s national security requirements for MCMs now and in the foreseeable future.

Nanotherapeutics has assembled a world class team of partners from throughout the United States to apply new biomanufacturing technologies with existing manufacturing capabilities for small molecule and biologic products that will provide the DOD with the ability to rapidly respond to CBRN events.

About Nanotherapeutics
Nanotherapeutics, Inc. is a privately held biopharmaceutical company with a major focus on developing a diversified proprietary pipeline of products having both biodefense and medical applications. Products under development include biodefense medical countermeasures, CNS, wound healing, addiction and pain, oncology, anti-infectives, vaccines and orthopedics. The Company has one FDA cleared injectable biologic, NanoFUSE® DBM used by orthopedic surgeons as bone graft filler. Nanotherapeutics has in-house cGMP manufacturing, formulation, and expertise in pre-clinical and clinical product development as well as clinical trial management to support its products. Established in 1999, the Company employs several proprietary platform technologies to manipulate and enhance the properties of drug candidates. For more information, visit the Company website at http://www.nanotherapeutics.com.

Read the full story at http://www.prweb.com/releases/2013/4/prweb10611645.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Selenium, Ltd. Awarded $500,000 SBIR Grant for Biofouling Prevention Technology
2. BioPharm Insight Journalist Awarded Fellowship by Association of Health Care Journalists
3. Cellular Dynamics and Coriell Institute for Medical Research Awarded Multi-Million Dollar Grants from California Institute for Regenerative Medicine to Manufacture and Bank Stem Cell Lines
4. Boston Heart Diagnostics Awarded $450,000 in Tax Incentives from the Massachusetts Life Sciences Center
5. S&D Marketing Advertising Awarded WBENC Certification
6. Island Abbey Foods Ltd CEO John Rowe Has Been Awarded the 2013 Food Industry Leadership Award by Food in Canada Magazine
7. Infinata's BioPharm Insight Journalist Awarded Fellowship by Association of Health Care Journalists
8. Fidelis Companies Certifies 14 Recruiters; Certified Personnel Consultant (CPC) and Certified Temporary-Staffing Specialist (CTS) Designation from NAPS Awarded
9. Boyd Coatings Awarded Workforce Training Grant
10. PNNL awarded $2.8 million to keep troops cool while using less fuel
11. University of Minnesota awarded $28 million grant to lead microelectronics development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory ... technical consulting, provides a free webinar on Performing Quality Investigations: Getting ... at 12pm CT at no charge. , Incomplete investigations are still a major ...
(Date:6/23/2016)... -- Amgen (NASDAQ: AMGN ) today announced a ... sciences incubator to accelerate the development of new therapies ... QB3@953 was created to help high-potential life science and ... stage organizations - access to laboratory infrastructure. ... "Amgen Golden Ticket" awards, providing each winner with one ...
(Date:6/22/2016)... 22, 2016 Cell Applications, Inc. and ... to produce up to one billion human induced ... one week. These high-quality, consistent stem cells enable ... and spend more time doing meaningful, relevant research. ... high-volume manufacturing process that produces affordable, reliable HiPSC ...
(Date:6/22/2016)... YORK , June 22, 2016  According ... growing next generation sequencing (NGS) market include significant ... of smaller sequencers.  More accessible and affordable sequencers, ... to growing demand for consumables including sample prep ... The Market for Sample Preparation for Next Generation ...
Breaking Biology Technology:
(Date:4/19/2016)... UAE, April 20, 2016 The ... as a compact web-based "all-in-one" system solution for all ... fingerprint reader or the door interface with integration authorization ... access control systems. The minimal dimensions of the access ... into the building installations offer considerable freedom of design ...
(Date:4/14/2016)... April 14, 2016 BioCatch ... Detection, today announced the appointment of Eyal Goldwerger ... role. Goldwerger,s leadership appointment comes at a ... of the deployment of its platform at several of ... technology, which discerns unique cognitive and physiological factors, is ...
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
Breaking Biology News(10 mins):